Searched for
BIOCON CEO
Biocon rolls out two biosimilars in US marketBiocon has launched two new biosimilar medicines, Bosaya and Aukelso, in the United States. These drugs treat serious bone conditions. They...- Trump's 100% tariff on patented drugs has limited impact on Indian pharma, rising protectionism a concern: Syngene MDThe recent decision by US President Donald Trump to impose a 100 per cent tariff on patented pharmaceutical imports to US is unlikely to ca...
- Biocon names insider Shreehas Tambe as MD & CEO for 5 years as Siddharth Mittal steps downBiocon announced a leadership change. Siddharth Mittal will step down as Managing Director and Chief Executive Officer on March 31. He will...
- Biocon to make Biocon Biologics a wholly owned subsidiaryBiocon is set to fully integrate its biosimilar arm, Biocon Biologics. This move will make Biocon Biologics a wholly owned subsidiary. Bioc...
- Biocon gets CDSCO nod for generic diabetes medicationBiocon has secured Indian regulatory approval for its generic Liraglutide drug substance and product, a version of Victoza, for treating Ty...
- Biocon launches diabetes, obesity management drug in UKBiocon has launched Liraglutide, a drug for diabetes and obesity management, in the UK under the brand names Liraglutide Biocon and Biolide...
- Biocon inks licensing, supply pact with Tabuk Pharmaceutical Manufacturing CoBiocon Ltd has signed a licensing and supply agreement with Tabuk Pharmaceutical Manufacturing Company to commercialise its GLP-1 products ...
- Biocon seeks partner to test generic Wegovy, Ozempic in ChinaIndia's Biocon is seeking a Chinese partner to conduct clinical trials on generic versions of Novo Nordisk's popular diabetes drug Ozempic ...
- Biocon inks licensing, supply pact with South Korea's Handok for chronic weight management productBiocon signs exclusive licensing agreement with Handok for commercialisation of synthetic Liraglutide in South Korea, expanding portfolio t...
- Biocon inks supply, distribution pact with Medix for chronic weight management drug in MexicoBiocon partners with Medix to distribute Liraglutide for chronic weight management in Mexico, offering affordable obesity treatment options...
- Biocon partners Biomm to commercialise diabetes drug in BrazilBiocon has partnered with Brazil-based Biomm SA for the commercialization of its diabetes drug, Semaglutide (gOzempic). Biocon will develop...
- New Group CEO is someone who understands Biocon's business synergy well: Kiran Mazumdar-Shaw"Peter, who is a veteran when it comes to the pharma and biopharma industry in terms of his global experience, also understands the Biocon ...
- Biocon appoints Peter Bains as Group CEO"I am delighted to welcome Peter to the Biocon Group in the role of Group CEO. Siddharth Mittal, CEO & MD Biocon Limited, Shreehas Tambe, C...
- Mylan-Biocon's breast cancer biosimilar gets ANVISA nodBiosimilar trastuzumab, indicated for breast cancer treatment, has been co-developed by Biocon and Mylan.
- Biocon introduces oncologic biosimilar KRABEVA in IndiaThe biosimilar product will be used for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervic...
- Biocon surges on USFDA's cancer drug approvalFor the quarter ended March 31, 2017, Biocon reported total revenue at Rs 632.10 crore and net profit stood at 203.80 crore.
- Mylan and Biocon make USFDA submission for proposed biosimilar trastuzumabThe submitted BLA includes a comprehensive package of analytical similarity, nonclinical and clinical data that consists of two pharmacokin...
- Biocon, Mylan drug discovery programme to treat cancer, arthritis makes progressBiocon today said two molecules for treating cancer and arthritis under the drug discovery programme with Mylan have entered global Phase 3...
- Panel set up to frame roadmap on use of Information Communication Technology in schoolsGovernment has set up a seven-member panel to suggest a roadmap for use of Information Communication Technology (ICT) tools in schools whic...
- Indian biotechnology sector to touch $ 5 bn by 2010: ReportIndian biotechnology sector is expected to become a five bn-dollar (around Rs 23,400 crore) industry by 2010, says a report.
Load More
